Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed pancreatic cancer~  * Locally advanced, metastatic, or recurrent disease~* Measurable or evaluable disease by physical exam, plain radiographs, CT scan, or MRI~* No brain metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy of 12 weeks or greater~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST ≤ 2.5 times ULN (5 times ULN if liver metastases are present)~* No chronic liver disease (i.e., chronic active hepatitis or cirrhosis)~* Creatinine ≤ 2.0 mg/dL~* No chronic renal disease~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier-method contraception during and for ≥ 3 months after completion of study treatment~* No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix~* No uncontrolled diabetes~* No active uncontrolled infection~* No other severe and/or uncontrolled medical disease~* HIV negative~PRIOR CONCURRENT THERAPY:~* No prior therapy for metastatic disease~  * Prior fluorouracil as a radiosensitizer for adjuvant therapy after surgery or for locally advanced disease is permitted if local disease has recurred or progressed ≥ 3 months after completion of therapy or disease is present outside the radiation field~* At least 2 weeks since prior major surgery~* No concurrent grapefruit or grapefruit juice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).